海正药业：子公司拟与华东院合作生物法合成肝素项目

Core Viewpoint - Haizheng Pharmaceutical (600267) announced a collaboration with East China Synthetic Biology Industry Technology Research Institute to develop and industrialize bioengineered heparin drugs using synthetic biology, with a project contract amount not exceeding 120 million yuan [1] Group 1 - The collaboration aims to enhance the company's product coverage in the field of synthetic biology [1] - The project is expected to promote the development of the synthetic biology industry [1] - The total contract amount for the project is capped at 120 million yuan [1]